Spots Global Cancer Trial Database for belzutifan
Every month we try and update this database with for belzutifan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) | NCT05030506 | Renal Cell Carc... | Belzutifan Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | NCT04976634 | Carcinoma, Hepa... Colorectal Neop... Pancreatic Duct... Biliary Tract N... Endometrial Neo... Esophageal Neop... | Pembrolizumab Belzutifan Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) | NCT05468697 | Renal Cell Carc... | Belzutifan Palbociclib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | NCT04195750 | Carcinoma, Rena... | Belzutifan Everolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | NCT03634540 | Renal Cell Carc... Clear Cell Rena... Kidney Cancer Renal Cancer Renal Cell Carc... Renal Cell Canc... Renal Cell Carc... Renal Cell Canc... Kidney | Belzutifan Cabozantinib | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | NCT04195750 | Carcinoma, Rena... | Belzutifan Everolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | NCT03401788 | VHL - Von Hippe... VHL Gene Mutati... VHL Syndrome VHL Gene Inacti... VHL-Associated ... VHL-Associated ... | Belzutifan | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | NCT06234605 | Renal Cell Carc... | HC-7366 Belzutifan | 18 Years - | HiberCell, Inc. | |
| A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | NCT06234605 | Renal Cell Carc... | HC-7366 Belzutifan | 18 Years - | HiberCell, Inc. | |
| A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | NCT04586231 | Carcinoma, Rena... | Belzutifan Lenvatinib Cabozantinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) | NCT05030506 | Renal Cell Carc... | Belzutifan Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | NCT03634540 | Renal Cell Carc... Clear Cell Rena... Kidney Cancer Renal Cancer Renal Cell Carc... Renal Cell Canc... Renal Cell Carc... Renal Cell Canc... Kidney | Belzutifan Cabozantinib | 18 Years - | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) | NCT05239728 | Carcinoma, Rena... | Belzutifan Pembrolizumab Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) | NCT04846920 | Carcinoma, Rena... | Belzutifan | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) | NCT04489771 | Carcinoma, Rena... | Belzutifan | 18 Years - | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
